#CTKB

2 weeks ago

Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Cytek Biosciences (Nasdaq: CTKB) reported Q4 2025 revenue of $62.1M (+8% YoY) and full-year 2025 revenue of $201.5M (+1% YoY). Recurring revenue grew 21% and comprised 34% of 2025 revenue. GAAP gross margin fell to 52% for 2025; adjusted EBITDA was $5.0M for the year. Net loss was $66.5M, reflecting a $33.1M non-cash valuation allowance on deferred tax assets. Installed base reached 3,664 instruments with 630 placements in 2025. Cytek initiated 2026 revenue guidance of $205M–$212M (2%–5% growth).

#CTKB Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results Cytek Biosciences (Nasdaq: CTKB) announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company expects full-year 2025 revenue of approximately $201 million and Q4 2025 revenue of approximately $62 million, representing Q4 growth of +8% year-over-year and +19% quarter-over-quarter. Management cited strength in Services, Reagents and Asia Pacific instrument revenue and a return to positive instrument growth in EMEA. Results are preliminary and subject to year-end close and audit. Cytek will report audited results and provide 2026 guidance near the end of February 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.

#CTKB Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Cytek Biosciences Reports Third Quarter 2025 Financial Results Cytek Biosciences (NASDAQ: CTKB) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $52.3M, up 2% year-over-year, with total installed base at 3,456 instruments (added 161 units). Total recurring revenue rose 19% and revenue from biotech/pharma/CRO customers grew 14%. GAAP gross profit was $27.6M and GAAP gross margin was 53% (adjusted gross margin 55% vs 60% prior year). Operating expenses increased 10% and G&A rose 47% due to litigation-related costs and a $0.7M one-time write-off. Net loss was $5.5M versus net income of $0.9M in Q3 2024. Adjusted EBITDA was $2.5M. Cash and marketable securities totaled $261.7M. Full‑year 2025 revenue guidance reaffirmed at $196M–$205M.

#CTKB Cytek Biosciences Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry Cytek Biosciences (NASDAQ: CTKB) announced a two-part initiative to expand global access to flow cytometry, partnering with the International Society for Advancement of Cytometry (ISAC).Phase one awards a three-laser Cytek Northern Lights full spectrum flow cytometer to an eligible lab. Phase two will launch a merit-based research grant program overseen by Cytek’s scientific advisory board, expected to debut in conjunction with CYTO 2026. The company cited prior collaboration with ISAC, including a donated Northern Lights system to a laboratory in Salta, Argentina, as an example of impact.Cytek framed the effort as expanding scientific equity by supporting under-resourced labs and enabling broader access to high-parameter immune monitoring and translational research.

#CTKB Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Cytek Biosciences Reports Second Quarter 2025 Financial Results Cytek Biosciences (Nasdaq: CTKB) reported Q2 2025 financial results, with total revenue of $45.6 million, marking a 2% decrease from Q2 2024. The company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025. Notable highlights include the launch of the Cytek Aurora™ Evo system and 16% growth in recurring revenue, which now accounts for 32% of trailing 12-month revenue.The company reported a net loss of $5.6 million and Adjusted EBITDA of $1.3 million. Cash position remained strong at $262.0 million. Cytek repurchased $4.5 million of common stock during Q2 and narrowed its 2025 revenue guidance to $196-205 million, projecting -2% to +2% growth over 2024.

#CTKB Cytek Biosciences Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Revolutionary Aurora Evo Flow Cytometer Doubles Speed, Adds Full Automation: Cytek's Game-Changing Launch New Aurora Evo system offers 2X faster sample processing, automated maintenance, and enhanced particle detection. See how this next-gen cytometer transforms research workflows.

#CTKB Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Cytek Biosciences Reports First Quarter 2025 Financial Results Cytek Biosciences (NASDAQ: CTKB) reported Q1 2025 financial results with total revenue of $41.5 million, marking a 7.6% decrease from Q1 2024. The company expanded its installed base to 3,149 instruments, adding 115 units in Q1. Key developments include commencing operations in Singapore for low-cost manufacturing and launching the Cytek Muse® Micro instrument. Financial highlights show a gross profit of $20.2 million (49% margin) and a net loss of $11.4 million. The company maintains a strong balance sheet with $265.6 million in cash and marketable securities. During Q1, Cytek repurchased $10.6 million of common stock. The company revised its 2025 revenue guidance to $196-210 million, projecting -2% to 5% growth over 2024.

#CTKB Cytek Biosciences Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Revolutionary Budget-Friendly Cell Analyzer Transforms Biotech Research Accessibility Cytek's new Muse Micro brings advanced 5-parameter flow cytometry to cell therapy and drug discovery markets with compact design and simplified analysis software.

#CTKB Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Mar 12th - #PCRX #THS #ZYXI #WNEB #VANI #TBCH #RGP #QTTB #MRTN #LTRY #KALA #IBCP #HCKT #CTKB #BIRD #AVR #SMP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Cytek Biosciences (CTKB) reported its Q4 and full-year 2024 financial results, showing mixed performance. Total revenue reached $200.5 million for FY2024, a 3.9% increase from 2023. The company expanded its installed base to 3,034 instruments, with 667 placements in 2024.The company reported a net loss of $6.0 million in 2024, improved from a $12.1 million loss in 2023. Adjusted EBITDA grew significantly to $22.4 million, up 77% year-over-year. Notable developments include opening a new manufacturing facility in Singapore and completing a share repurchase of 3,971,624 shares for $21.6 million.Looking ahead to 2025, Cytek projects revenue between $204-212 million, representing 2-6% growth. The company also announced an additional $50 million stock repurchase program for 2025.

#CTKB Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Cytek Biosciences Projects 4% Revenue Growth to $201M for 2024, Mixed Q4 Performance Cytek Biosciences expects 2024 revenue of $200-201M despite forex headwinds. Q4 shows strong sequential growth but flat YoY, with regional variations in performance.

#CTKB Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #CTKB ) (CTKB) Investment Analysis

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Cytek Biosciences Announces New $50 Million Share Buyback Program for 2025 Cytek Biosciences unveils plans for a fresh $50M stock repurchase initiative starting January 2025, showcasing confidence in long-term growth and shareholder value.

#CTKB Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#CTKB Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#CTKB Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

www.stocktitan.net/news/CTKB/cytek-bioscien...

0 0 0 0

Posts tagged #CTKB